Medtronic, Inc. Stock Nyse
Equities
US5850551061
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- USD | - |
05-09 | Arecor Therapeutics collaborates with Medtronic on novel insulin | AN |
05-09 | Arecor Therapeutics, Medtronic Team Up for Thermostable Insulin Development | MT |
Sales 2024 * | 32.24B 44.08B | Sales 2025 * | 33.57B 45.9B | Capitalization | 110B 150B |
---|---|---|---|---|---|
Net income 2024 * | 4.56B 6.24B | Net income 2025 * | 5.24B 7.17B | EV / Sales 2024 * | 4.1 x |
Net Debt 2024 * | 22.21B 30.37B | Net Debt 2025 * | 21.12B 28.88B | EV / Sales 2025 * | 3.91 x |
P/E ratio 2024 * |
23.6
x | P/E ratio 2025 * |
20.5
x | Employees | - |
Yield 2024 * |
3.32% | Yield 2025 * |
3.49% | Free-Float | 99.81% |
Latest transcript on Medtronic, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Geoffrey Martha
CEO | Chief Executive Officer | 54 | 15-01-25 |
Karen Parkhill
DFI | Director of Finance/CFO | 58 | 16-05-31 |
Gregory Smith
COO | Chief Operating Officer | 63 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Donnelly
BRD | Director/Board Member | 62 | 12-12-31 |
Kendall Powell
BRD | Director/Board Member | 70 | 06-12-31 |
Randall Hogan
BRD | Director/Board Member | 68 | 14-12-31 |
1st Jan change | Capi. | |
---|---|---|
-4.78% | 182B | |
-3.23% | 68.11B | |
+1.01% | 50.53B | |
+9.29% | 44.8B | |
+2.84% | 40.7B | |
+21.22% | 32.25B | |
+2.69% | 26.53B | |
+15.25% | 25.02B | |
-1.59% | 24.96B |